PMV Pharmaceuticals stock moves above 200-day average as analysts stay mixed

PMV Pharmaceuticals stock moved into focus after MarketBeat reported on October 29, 2026, that the shares had traded above the company's 200-day moving average. The report placed the 200-day average at 1.30 USD and said the stock traded as high as 1.39 USD during the session.

MarketBeat also described a mixed analyst picture. Its cited research coverage included buy ratings from HC Wainwright and Ladenburg Thalmann, while Weiss Ratings had maintained a negative assessment. Based on the data cited in the report, the average rating was Moderate Buy, with a consensus price target of 4.33 USD. These figures reflect analyst opinions rather than a guarantee of future performance.

For investors, the more important issue remains PMV's clinical development path. PMV Pharmaceuticals describes itself as a precision oncology company developing small-molecule therapies intended to target mutations in the tumor-suppressor protein p53. Its lead candidate, rezatapopt, is being developed for tumors containing the p53 Y220C mutation, according to the company profile on its investor-relations website.

The latest available PMVP quote was 1.35 USD at 22:00 Berlin time on October 29, down 2.17 percent from the previous close of 1.38 USD. This is a US-listed dollar quote, not a verified Xetra close, so it should not be interpreted as a euro-denominated German exchange comparison.

Investors can follow the real-time quote of PMV Pharmaceuticals stock for subsequent market updates.

For broader market context, the S&P 500 remains the relevant US equity benchmark, although index direction does not by itself explain movements in an individual clinical-stage biotechnology company.

More news and analyses on PMV Pharmaceuticals stock.